Cost-effectiveness of rituximab in maintenance treatment of refractory or relapsing follicular non-Hodgkin lymphoma;Costo-efficacia di rituximab nella terapia di mantenimento in soggetti affetti da linfoma non-Hodgkin follicolare refrattario o recidivante

PharmacoEconomics - Italian Research Articles

Volumn 9, Issue 1, 2007, Pages 9-19

  Berto, Patrizia ^a   Lopatriello, S ^a   Arcaini, L ^b   Del Poeta, G ^c   Martelli, M ^d   Gargantini, L ^e   Vitolo, U ^f  

^a Pbe Consulting   (Italy)

^b FONDAZIONE IRCCS POLICLINICO SAN MATTEO   (Italy)

^c UNIVERSITY OF ROME TOR VERGATA   (Italy)

^d POLICLINICO UMBERTO I   (Italy)

^e OSPEDALE NIGUARDA CA GRANDA   (Italy)

^f MOLINETTE HOSPITAL   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA2B INTERFERON; CHLORAMBUCIL; CYCLOPHOSPHAMIDE; FLUDARABINE; PREDNISONE; RITUXIMAB; VINCRISTINE;

ARTICLE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; COST OF ILLNESS; COST UTILITY ANALYSIS; DRUG COST; FOLLOW UP; HEALTH STATUS; HUMAN; KAPLAN MEIER METHOD; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; NONHODGKIN LYMPHOMA; OVERALL SURVIVAL; POPULATION DYNAMICS; PROBABILITY; QUALITY ADJUSTED LIFE YEAR; QUALITY OF LIFE; QUESTIONNAIRE; RECURRENT DISEASE; SENSITIVITY ANALYSIS; TAX; TREATMENT DURATION; TREATMENT OUTCOME;

EID: 34548814129     PISSN: 15909158     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF03320566     Document Type: Article

References (37)

1. Crocetti R, Capocaccia R, Casella C, et al., and the Network of the Italian Cancer Registries (AIRT). Population based incidence and mortality cancer trends (1986-1997) from the Network of Italian Cancer Registries. Eur J Cancer Prev 2004; 13: 287-295
2. Ansell SM, Armitage J. Non-Hodgkin lymphoma: diagnosis and treatment. Mayo Clin Proc 2005; 80: 1087-97
3. Hiddeman W, Unterhalt M. Stand und Perspektiven in der therapie follikulare keimzentrumslymphome. Dtsch arzteblatt 1998; 95: heft 50
4. Herold M, Sacchi S, Hieke K. The cost of treating relapsed indolent non-Hodgkin's lymphoma in an international setting: retrospective analysis of resource use. Haematologica 2002; 87: 719-29
5. Hamblin T, Best H J, Morris J, Hornberger J. Cost-effectiveness of rituximab in treatment of diffuse large B-cell lymphoma. Abstract and poster presented at the 42 British Society of Haematology (BSH) Conference, 20 April 2002, Brighton, United Kingdom
6. Best JH, Hornberger J, Proctor SJ, et al. Cost-effectiveness analysis of rituximab combined with CHOP for treatment of diffuse large B-cell lymphoma. Value Health 2005; 8: 462-70
7. Hornberger J, Lewis G. Cost-utility of rituximab in diffuse large B-cell lymphoma. Eur J Cancer 2003; Suppl., vol 1, no3 S3 [abstract]
8. Malliti M, Junot H, Fievet MH, et al. Treatment of malignant non-Hodgkin's lymphoma. Economic impact of rituximab (Mabthera) versus conventional chemotherapy. Ann Méd Interne (Paris) 2003; 154: 139-47
9. Knight C, Hind D, Brewer N, Abbott V Rituximab (MabThera) for aggressive non-Hodgkin's lymphoma: systematic review and economic evaluation. Health Technol Assess 2004; 8: iii, ix-xi, 1-82
10. Groot MT, Lugtenburg PJ, Hornberger J, et al. Cost-effectiveness of rituximab (MabThera) in diffuse large B-cell lymphoma in The Netherlands. Eur J Haematol 2005; 74: 194-202
11. Hieke K, Herold M. Adding rituximab to standard chemotherapy is cost neutral and clinically superior in advanced stage Non-Hodgkin's Lymphoma (NHL). Value Health 2006; 9: A282
12. Berto P, Morsanutto A, Lopatriello S, et al. Analisi costo-efficacia di rituximab + CHOP versus CHOP in soggetti affetti da linfoma non-Hodgkin aggressivo. Pharmacoeconomics-Italian Research Articles 2004, 6: 151-60
13. Van Agthoven M, Hagenbeek A, Uyl-de Groot CA. Costs of common treatment options for indolent follicular non-Hodgkin's lymphoma. Value Health 2005; 8: A40
14. Hieke K, Herold M. Adding rituximab to standard chemotherapy appears dominant vs. chemotherapy alone in advanced stage NHL - interim results from a randomized clinical trial (RCT). Value Health 2005; 8: A38
15. Maturi B, Tong W, Gyldmark M, et al. Cost effectiveness of rituximab plus CVP in previously untreated indolent Non-Hodgkin's lymphoma. Value Health 2006; 9: A288
16. Sweetenham J, Hieke K, Kerrigan M, et al. Cost-minimization analysis of CHOP, fludarabine and rituximab for the treatment of relapsed indolent B-cell non-Hodgkin's lymphoma in the U.K. Br J Haematol 1999; 106: 47-54
17. Wake B, Hyde C, Bryan S, et al. Rituximab as third-line treatment for refractory or recurrent Stage III or IV follicular non-Hodgkin's lymphoma: a systematic review and economic evaluation. Health Technol Assess 2002; 6: 1-85
18. van Oers MH, Klasa R, Marcus RE, et al. Rituximab maintenance improves clinical outcome of relapsed/resistant follicular non-Hodgkin lymphoma in patients both with and without rituximab during induction: results of a prospective randomized phase-3 intergroup trial. Blood 2006; 108: 3295-301
19. Ghielmini M, Schmitz SF, Cogliatti SB, et al. Prolonged treatment with rituximab in patients with follicular lymphoma significantly increases event-free survival and response duration compared with the standard weekly x 4 schedule. Blood 2004; 103: 4416-23
20. Hainsworth JD, Litchy S, Shaffer DW, et al. Maximizing therapeutic benefit of rituximab: maintenance therapy versus re-treatment at progression in patients with indolent non-Hodgkin's lymphoma - a randomized phase II trial of the Minnie Pearl Cancer Research Network. J Clin Oncol 2005; 23: 1088-95
21. Dreyling M, Forstpointner R, Gramatzki M, et al. Rituximab maintenance improves progression-free and overall survival rates after combined immuno-chemotherapy (R-FCM) in patients with relapsed follicular and mantle cell lymphoma: final results of a prospective randomised trial of the German Low Grade Lymphoma Study Group (GLSG). J Clin Oncol 2006; 24 (Suppl.): 7502
22. Maturi B, Mikhael J, Dunlop W, et al. Maintenance therapy with rituximab for follicular lymphoma is cost-effective - a Canadian perspective. Proceedings of "ASH-Congress", Orlando, Florida, 9-12 December, 2006 [abstract]
23. Briggs A, Sculpher M. An introduction to Markov modelling for economic evaluation. PharmacoEconomics 1998; 13: 397-409
24. Oxford Outcomes Ltd. Utility values in Follicular Lymphoma. 16/12/2005 (data on file).
25. Ballatori E, Berto P, Roila F. L'analisi farmacoeconomica in oncologia. Roma: Il Pensiero Scientifico Editore, 1999
26. Brazier J, Roberts J, Tsuchiya A, Busschbach J. A comparison of the EQ-5D and SF-6D across seven patient groups. Health Econ 2004; 13: 873-84
27. Brazier J, Roberts J, Tsuchiya A. A comparison of the EQ-5D and SF-6D across seven patient groups. Proceedings of the 18th Plenary Meeting of the EuroQol Group Copenhagen. 6th-7th September 2001:9-33
28. Abdalla M, Russell I. Tariffs for the EuroQol health states based on modelling the individual VAS and TTO data of the York survey. EuroQol Plenary Meeting. London, October 1994; 75-93
29. www.giofil.it, accesso luglio 2006
30. Ministero della Salute, 1996
31. Conferenza delle Regioni e Province Autonome. Tariffa Unica Convenzionale per le prestazioni di assistenza ospedaliera. Regole e tariffe valide per l'anno 2006. Roma, 15 dicembre 2005
32. www.ibmdr.galliera.it accesso del 29/08/2006
33. www-ministerosalute.it. Schede di Dimissione Ospedaliera, accesso del 29/08/2006
34. FASI Nomenclatore-Tariffario. Edizione 2006. www.fasi.it, accesso luglio 2006
35. Dillon A. Managing new health technologies in the UK. In: Atti del Convegno: "Il Technology Assessment: quale influenza sulle scelte istituzionali e quale impatto sul mercato dei farmaci e delle tecnologie e sull'offerta di prestazioni sanitarie". Università L. Bocconi, Milano, 27 ottobre 2005
36. Messori A, Santarlasci B, Trippoli S, Vaiani M. Controvalore economico del farmaco e beneficio clinico: stato dell'arte della metodologia di applicazione di un algoritmo farmacoeconomico. Pharmacoeconomics-Italian Research Articles 2003; 5: 53-67
37. http://www.eurocambi.com/ riferito a dicembre 2006